Medicines Transparency Alliance (MeTA)

Itad has begun to evaluate the Medicines Transparency Alliance (MeTA). MeTA is an innovative model, which seeks to increase access to essential medicines through improved transparency in the medicines supply chain. It is led by multi-stakeholder councils at the country level involving government officials, civil society representatives and private sector representations. They collate and analyse information on access to medicines and the medicines supply chain to identify key bottlenecks that can be addressed through joint action to promote more evidence-based policy and greater access to quality medicines. The initiative was launched by DFID in collaboration with WHO and the World Bank.  It draws on the model piloted through the Extractive Industries Transparency Initiative.

The evaluation seeks to determine whether MeTA has been effective. This involves testing whether improved transparency and multi-stakeholder collaboration is an effective means of increasing the availability and affordability of essential medicines. Itad’s team of seven consultants will apply a rigorous theory-based evaluation methodology based on Qualitative Comparative Analysis (QCA). This will allow the team to identify the casual packages of factors that bring about evidence-based policy change in the medicines sector. The results from QCA analysis will then be ground-truthed through 3 country visits to some of the 7 MeTA pilot countries (Ghana, Jordan, Kyrgyzstan, Peru, Philippines, Uganda and Zambia). The evaluation started in August 2014 and will be completed in August 2015.